Internal Medicine, Rheumatology · New York, NY
NPI
1740256908
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
51 Saint Nicholas Ave, Apt Ph-3f
New York, NY, 10026
Phone (212) 360-5752
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
2,331 services
Medicare patients, 2024
49
Average age 71
Drug cost, 2024
$4.7M
4,650 prescriptions
Company payments, 2025
$6,186
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Naarendorp was code 99214 (office e&m - established), 125 times for 44 patients. In total Michael Naarendorp billed 2,331 services in 19 codes, and Medicare paid $46K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-03-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 125 | 44 | $107.27 | $13K |
| 99213 Office E&M - Established | Office | 101 | 30 | $74.01 | $7,475 |
| 99203 Office E&M - New | Office | 16 | 16 | $90.27 | $1,444 |
| 77080 Standard X-ray | Office | 12 | 12 | $43.99 | $528 |
By year: 2022 $61K for 1,334 services; 2023 $35K for 1,128 services; 2024 $46K for 2,331 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Naarendorp prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 692 prescriptions and refills. In total Michael Naarendorp wrote 4,650 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 692 | 777 | 112 | $12K |
| Prednisone Generic | 387 | 400 | 137 | $1,768 |
| Gabapentin Generic | 314 | 325 | 83 | $1,465 |
| Hydroxychloroquine Sulfate Generic | 280 | 336 | 47 | $6,185 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 274 | 283 | 58 | $327 |
| Naproxen Generic | 262 | 270 | 75 | $2,098 |
| Alendronate Sodium Generic | 209 | 216 | 41 | $639 |
| Folic Acid Generic | 208 | 237 | 43 | $174 |
| Ibuprofen Generic | 171 | 171 | 55 | $1,420 |
| Cyclobenzaprine Hcl Generic | 141 | 141 | 38 | $539 |
| Actemra Tocilizumab | 120 | 120 | 13 | $427K |
| Allopurinol Generic | 93 | 101 | 14 | $648 |
| Humira(Cf) Pen Adalimumab | 93 | 93 | 12 | $610K |
| Xeljanz Xr Tofacitinib Citrate | 90 | 96 | Under 11 | $531K |
| Enbrel Mini Etanercept | 88 | 88 | Under 11 | $627K |
Brand drugs: - claims; generic drugs: 3,686 claims; opioid claims: 36.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Naarendorp $6,186 ($6,186 in general payments such as food, travel and fees) from 21 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,056.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 25 | $1,056 |
| Amgen Inc. AMGN | 21 | $933 |
| Pfizer Inc. PFE | 40 | $607 |
| UCB, Inc. UCB.BR | 16 | $599 |
| Abbvie Inc. ABBV | 19 | $585 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $350 |
| Aurinia Pharma U.S., Inc. AUPH | 6 | $276 |
| Lilly USA, LLC LLY | 11 | $268 |
| CSL Behring CSL.AX | 10 | $264 |
| Alexion Pharmaceuticals, Inc. AZN | 6 | $256 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.